Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MGAM | O43451 | 5/20 | 0.62 |
| ▸ | GAA | P10253 | 5/20 | 0.62 |
| ▸ | SI | P14410 | 5/20 | 0.62 |
| ▸ | MGAM2 | Q2M2H8 | 5/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833531 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL11331186 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL11337791 | 0.79 | ALDH1A1 (1.00) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL368725 | 0.79 | KDM4E (0.65) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL11324204 | 0.79 | HSD17B1 (0.76) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL3829254 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL8042130 | 0.79 | HSD17B1 (0.46) | KDM4EALDH1A1MEN1KMT2ANOTUM | |
| SCHEMBL3819147 | 0.78 | TAAR1 (0.49) | KDM4EALDH1A1MEN1KMT2ANOTUM | |
| SCHEMBL1143676 | 0.77 | KDM4E (1.00) | KDM4EALDH1A1MEN1KMT2AMGAM | |
| SCHEMBL45441 | 0.77 | KDM4E (0.67) | KDM4EALDH1A1MEN1KMT2AMGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221668-A | Indometacin derivative containing 2-amino-1, 3, 4-thiadiazole and preparation method and application thereof | 华南农业大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-112920181-A | N- (5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound | 中国医科大学 | 2021-06-08 | — | — | CN | disclosed |
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-105228982-A | 3-acetylamino-1- (phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino) benzene derivatives for the treatment of hyperproliferative disorders | Bayer Pharma AG | 2016-01-06 | — | — | CN | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| EP-2391611-B1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2391611-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | KDM4E 2232/4885ALDH1A1 264/4885MEN1 368/4885 |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | KDM4E 4417/4885ALDH1A1 126/4885MEN1 1432/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | KDM4E 2327/4885ALDH1A1 277/4885MEN1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.